Regulus Therapeutics Inc.
RGLS
Classifica tra le azioni
#17280
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Prezzo delle azioni
$8.16
Ultima sincronizzazione: 2025-06-26
Capitalizzazione di mercato
$234.57M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-56.96%
Paese
US
Scambia Regulus Therapeutics Inc. (RGLS)
Categoria
Healthcare
Storico del prezzo dell'azione per Regulus Therapeutics Inc. (RGLS)
Prezzo di chiusura più alto: $18.90 il 2024-08-01
Prezzo di chiusura più basso: $25.97 il 2018-04-01
Prezzo di chiusura più basso: $25.97 il 2018-04-01
Storico del prezzo dell'azione di Regulus Therapeutics Inc. dal 2018 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2024 | 115.52% |
| 2023 | 128.77% |
| 2022 | -59.49% |
| 2021 | -66.20% |
| 2020 | -18.96% |
| 2019 | 28.12% |
| 2018 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $525.41 | 23.26% |
US
|
|
| $252.59 | 818.83% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $887.75 | 6.35% |
NL
|
|
| $752.87 | 7.40% |
CH
|
